UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype

Clinical pharmacology and therapeutics, 2012-02, Vol.91 (2), p.321-326

2012

Volltextzugriff (PDF)

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

Clinical pharmacology and therapeutics, 2017-07, Vol.102 (1), p.37-44

2017

Volltextzugriff (PDF)

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

Clinical pharmacology and therapeutics, 2015-08, Vol.98 (2), p.127-134

2015

Volltextzugriff (PDF)

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

Clinical pharmacology and therapeutics, 2017-07, Vol.102 (1), p.37-44

2017

Volltextzugriff (PDF)

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

Clinical pharmacology and therapeutics, 2014-04, Vol.95 (4), p.376-382

2014

Volltextzugriff (PDF)

Age-Related Changes in MicroRNA Expression and Pharmacogenes in Human Liver

Clinical pharmacology and therapeutics, 2015-08, Vol.98 (2), p.205-215

2015

Volltextzugriff (PDF)

Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling

Oncogene, 2003-10, Vol.22 (47), p.7316-7339

2003

Volltextzugriff (PDF)

Implementation of a pharmacogenomics consult service to support the INGENIOUS trial

Clinical pharmacology and therapeutics, 2016-07, Vol.100 (1), p.63-66

2016

Volltextzugriff (PDF)

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen

Cancer chemotherapy and pharmacology, 2005-05, Vol.55 (5), p.471-478

2005

Volltextzugriff (PDF)

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

Breast cancer research and treatment, 2004-05, Vol.85 (2), p.151-159

2004

Volltextzugriff (PDF)

Cellular and molecular pharmacology of antiestrogen action and resistance

Pharmacological reviews, 2001-03, Vol.53 (1), p.25

2001

Volltextzugriff (PDF)

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study

Breast cancer research and treatment, 2017-11, Vol.166 (1), p.277-287

2017

Volltextzugriff (PDF)

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real‐World Setting

Clinical and translational science, 2017-05, Vol.10 (3), p.143-146

2017

Volltextzugriff (PDF)

Considerations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy

Clinical chemistry (Baltimore, Md.), 2015-05, Vol.61 (5), p.775-776

2015

Volltextzugriff (PDF)

Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis

Carcinogenesis (New York), 2005-09, Vol.26 (9), p.1527-1535

2005

Volltextzugriff (PDF)

Rifampin modulation of xeno‐ and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes

Pharmacology research & perspectives, 2018-04, Vol.6 (2), p.e00386-n/a

2018

Volltextzugriff (PDF)

Abstract P6-09-11: Genetic variation in CYP3A affects steady-state exemestane concentrations but does not explain inter-race difference

Cancer research (Chicago, Ill.), 2017-02, Vol.77 (4_Supplement), p.P6-P6-09-11

2017

Volltextzugriff (PDF)

Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy

Clinical interventions in aging, 2015-01, Vol.10, p.269-275

2015

Volltextzugriff (PDF)

Association Between the CYP3A5 Genotype and Blood Pressure

Hypertension (Dallas, Tex. 1979), 2005-02, Vol.45 (2), p.294-298

2005

Volltextzugriff (PDF)

Abstract P5-12-05: CYP3A422 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P5-P5-12-05

2016

Volltextzugriff (PDF)

Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant)

Cancer research (Chicago, Ill.), 2004-06, Vol.64 (11), p.4030-4039

2004

Volltextzugriff (PDF)

MCF7/LCC9 : An antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen

Cancer research (Chicago, Ill.), 1997-08, Vol.57 (16), p.3486-3493

1997

Volltextzugriff (PDF)

Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-κB, and cyclic AMP response element binding with acquired resistance to faslodex (ICI 182,780)

Cancer research (Chicago, Ill.), 2002-06, Vol.62 (12), p.3428-3437

2002

Volltextzugriff (PDF)

Molecular and pharmacological aspects of antiestrogen resistance

Journal of steroid biochemistry and molecular biology, 2001-01, Vol.76 (1), p.71-84

2001

Volltextzugriff (PDF)

Impact of SNPs in ERα corepressor SMRT on breast cancer risk and response to endocrine therapy

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.1043

2009

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(33)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(35)

Sprache

Englisch
(35)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

Age-Related Changes in MicroRNA Expression and Pharmacogenes in Human Liver

Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling

Implementation of a pharmacogenomics consult service to support the INGENIOUS trial

Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen

Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen

Cellular and molecular pharmacology of antiestrogen action and resistance

CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study

The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real‐World Setting

Considerations for the Utility of the CPIC Guideline for CYP2D6 Genotype and Codeine Therapy

Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis

Rifampin modulation of xeno‐ and endobiotic conjugating enzyme mRNA expression and associated microRNAs in human hepatocytes

Abstract P6-09-11: Genetic variation in CYP3A affects steady-state exemestane concentrations but does not explain inter-race difference

Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy

Association Between the CYP3A5 Genotype and Blood Pressure

Abstract P5-12-05: CYP3A422 polymorphism is associated with increased exemestane concentrations in postmenopausal breast cancer patients

Interferon regulatory factor-1 mediates the proapoptotic but not cell cycle arrest effects of the steroidal antiestrogen ICI 182,780 (faslodex, fulvestrant)

MCF7/LCC9 : An antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen

Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-κB, and cyclic AMP response element binding with acquired resistance to faslodex (ICI 182,780)

Molecular and pharmacological aspects of antiestrogen resistance

Impact of SNPs in ERα corepressor SMRT on breast cancer risk and response to endocrine therapy

Suchergebnisse filtern